Global Auto-Injectors Market Report 2022 to 2027: Increasing Demand for Convenience of Patients Drives Growth – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Auto-Injectors Market – Growth, Trends, COVID-19 Impact, and Forecasts (2022 – 2027)” report has been added to ResearchAndMarkets.com’s offering.
The global auto-Injectors market is expected to witness a CAGR of 20.7% during the forecast period.
Companies Mentioned
- Abbvie
- Amgen
- AstraZeneca
- Bayer
- Becton, Dickinson and Company
- Biogen
- Eli Lilly
- Novartis
- Teva Pharmaceuticals
- Ypsomed
Key Market Trends
Rheumatoid Arthritis Expected to Hold Significant Market Share
Rheumatoid arthritis (RA) is an autoimmune disease in which the body’s immune system attacks the joints, causing inflammation of the synovium and swelling and pain in and around the joints. According to the article published in Rheumatology International in July 2021, titled ” The global prevalence of rheumatoid arthritis: a meta-analysis based on a systematic review” the global prevalence of RA between 1980 and 2019 was 460 per 100,000 population. Thus Increasing prevalence of RA is expected to boost the segment growth.
Arthritis primarily affects the elderly population, with females having a higher prevalence than males. According to the United Nations World Population Prospects 2019 report, one in every six people in the world will be 65 or older by 2050, up from one in every eleven in 2019, and one in every four people in Europe and Northern America will be 65 or older by 2050. The number of persons aged 80 years or over globally is projected to triple, from 143 million in 2019 to 426 million in 2050. As arthritis is more prevalent in the geriatric population and increasing it boost the segment over the forecast period.
According to several recent studies, the majority of the patients with rheumatoid arthritis who used an autoinjector for the treatment were observed to be comfortable using the device and even had better outcomes than those who had someone else administer injections.
North America Expected to Dominate the Market
North America is expected to hold a significant share of the global disposable auto-injectors market during the forecast period. The factors such as early adoption of technologically advanced products and product approvals as well rising prevalence of chronic diseases boost the market in the region.
According to the data provided by the Canadian government, in 2019, 44% of adults aged 20+ years have at least 1 of 10 common chronic conditions, and the prevalence of chronic diseases is rising. Furthermore, a high incidence of chronic diseases, such as cancers, boosts the market in the region.
According to the Globocon 2020, the number of new cancer cases diagnosed was 2,281,658 in the United States in 2020, with 612,390 deaths. Among all cancers, breast cancer had the highest incidence with 253,465 cases, followed by lung (227,875), prostate (209,512), and colon (101,809).
Furthermore, rising technological advancements, increasing entry of new players, and speedy adoption of advanced products are helping in the market growth in the United States. For example, in October 2019, AstraZeneca received FDA approval for the self-administration of Fasenra (benralizumab) in a pre-filled, single-use auto-injector from the United States Food and Drug Administration.
Thus, all aforementioned factors are expected to boost the segment.
Key Topics Covered:
1 INTRODUCTION
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Demand for Convenience of Patients
4.2.2 Rising Incidence of Chronic and Lifestyle Diseases
4.2.3 Technological Advancements
4.3 Market Restraints
4.3.1 Preference for Alternative Drug Delivery Modes
4.3.2 Regulatory Hurdles
4.4 Porter’s Five Force Analysis
5 MARKET SEGMENTATION (Market Size by Value – USD million)
5.1 Application
5.2 Type
5.3 End User
5.4 Geography
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
For more information about this report visit https://www.researchandmarkets.com/r/s14as5
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
